IGM Biosciences Inc (NAS:IGMS)
$ 7.24 -0.07 (-0.96%) Market Cap: 427.33 Mil Enterprise Value: 174.49 Mil PE Ratio: 0 PB Ratio: 2.65 GF Score: 34/100

IGM Biosciences Inc at Barclays Global Healthcare Conference Transcript

Mar 11, 2020 / 07:20PM GMT
Release Date Price: $52.32 (+3.79%)
Peter Richard Lawson
Barclays Bank PLC, Research Division - Research Analyst

Good afternoon. Welcome to Barclays Global Healthcare Conference. My name is Peter Lawson. I'm one of the biotech analysts at Barclays. It gives me great pleasure to introduce Misbah Tahir, CFO; and Angus Sinclair, VP of Immuno-Oncology from IGM Biosciences.

Questions & Answers

Peter Richard Lawson
Barclays Bank PLC, Research Division - Research Analyst

And maybe just as kind of a kickoff question, Misbah, perhaps you could kind of just give us a general high-level introduction on the pipeline and therapeutic focus and burn rate at the moment.

Misbah Tahir
IGM Biosciences, Inc. - CFO

Yes, happy to do so. And Peter, first, thank you for having us at this conference and giving us the opportunity to speak. Really excited to be here.

IGM, in a nutshell, is the global leader in the development of engineered IgM antibodies. We believe what we're doing is really different from anyone else out there in the field, and we're

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot